CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19<sup>+</sup>HLA-C1<sup>−</sup> Malignant B Cells While Sparing CD19<sup>+</sup>HLA-C1<sup>+</sup> Healthy B Cells

CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19<sup>+</sup>HLA-C1<sup>−</sup> Malignant B Cells While Sparing CD19<sup>+</sup>HLA-C1<sup>+</sup> Healthy B Cells

B cell aplasia caused by “on-target off-tumor” toxicity is one of the clinical side effects during CD19-targeted chimeric antigen receptor (CAR) T (CD19-CAR-T) cells treatment for B cell malignancies. Persistent B cell aplasia was observed in all patients with sustained remission, which increased th...

Full description

Bibliographic Details
Main Authors: Lei Tao, Muhammad Asad Farooq, Yaoxin Gao, Li Zhang, Congyi Niu, Iqra Ajmal, Ying Zhou, Cong He, Guixia Zhao, Jie Yao, Mingyao Liu, Wenzheng Jiang
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cancers
Subjects:
CD19-CAR-T
B cell aplasia
KIR
PD-1
inhibitory CAR
Online Access:https://www.mdpi.com/2072-6694/12/9/2612

Similar Items

Similar Items